Goad, PharmD, MPH, of Chapman University explains why pharmacists are trusted, accessible sources for COVID-19 vaccine ...

Gray market peptides cause vague symptoms patients may not disclose or link, so serious harms can go unnoticed until late, ...

MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, ...

Telitacicept has the first regulatory approval for Sjögren disease (China), while global phase 3 programs aim to support ...

Without a functioning ACIP, Jeffery Goad, PharmD, MPH, explains who now guides COVID-19 vaccine use and how HMOs can stock ...

Gray market peptides cause vague symptoms patients may not disclose or link, so serious harms can go unnoticed until late, says Catherine Varney, DO. 259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512 ...

FDA authorized frontline pirtobrutinib for previously untreated CLL/SLL without known 17p deletion, expanding use beyond its established relapsed/refractory setting after covalent BTK inhibition.

BC, discusses how data builds payer trust, reduces prior authorization, and expands access in community oncology. In one of its most recent pilots, AON partnered with Evolent Health and a specific ...

Michael Wechsler, MD, of National Jewish Health, discusses how twice yearly depemokimab reduces exacerbation risk in patients with T2 asthma. The findings suggest twice yearly dosing may offer early ...

Type 2 (T2)-high and T2-low asthma are distinguishable by unique transcriptomic networks, but characterization of T2-low asthma remains relatively poo ...

Contact sensitization was detected in 79.6% of hand eczema patients, with 33.3% polysensitized and 46.3% reacting to a single allergen on baseline series testing. Nickel sulfate and fragrance mix 1 ...

CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed. 259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512 ...